Superscan in First Posttherapeutic 177Lu-PSMA Scan

被引：0

作者：

Tobar, Merve Nida Calderon ^{[1
]}

Yilmaz, Farise ^{[1
]}

Perktas, Lutfu ^{[1
]}

机构：

[1] Selcuk Univ, Fac Med, Dept Nucl Med, Celal Bayar St 313, TR-42250 Konya, Turkiye

来源：

CLINICAL NUCLEAR MEDICINE | 2025年 / 50卷 / 04期

关键词：

superscan; Lu-177-PSMA; full response;

D O I：

10.1097/RLU.0000000000005624

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This case highlights the effectiveness of Lu-177-PSMA therapy in a 70-year-old man with castration-resistant prostate cancer who has extensive skeletal metastases in posttherapeutic whole-body imaging. A 70-year-old man with extensive skeletal metastases underwent 4 cycles of (177) Lu-PSMA-617 therapy. A whole-body Lu-177-PSMA scan after the first cycle showed diffuse skeletal lesions, with minimal PSMA uptake in the kidneys and salivary glands. A whole-body scan after the fourth cycle of Lu-177-PSMA showed a complete response of skeletal metastases with normal PSMA uptake in the kidneys and salivary glands. According to REC & Idot;P 1.0, the patient was considered a complete response.

引用

页码：e248 / e249

页数：2

共 8 条

[1] [Anonymous], 2023, J Nucl Med, p64(suppl1)
[2] 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy
Aryana, Kamran
Moghadam, Soroush Zarehparvar
Salek, Roham
Divband, Ghasemali
[J]. CLINICAL NUCLEAR MEDICINE, 2018, 43 (04) : 273 - 275
[3] RECIP 1.0 Predicts Progression-Free Survival After [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Gafita, Andrei
Djaileb, Loic
Rauscher, Isabel
Fendler, Wolfgang P.
Hadaschik, Boris
Rowe, Steven P.
Herrmann, Ken
Solnes, Lilja B.
Calais, Jeremie
Rettig, Matthew B.
Weber, Manuel
Farolfi, Andrea
Benz, Matthias R.
Eiber, Matthias
[J]. JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (06) : 917 - 922
[4] Gafita Andrei, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_350946
[5] Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
Gafita, Andrei
Fendler, Wolfgang P.
Hui, Wang
Sandhu, Shahneen
Weber, Manuel
Esfandiari, Rouzbeh
Calais, Jeremie
Rauscher, Isabel
Rathke, Hendrik
Tauber, Robert
Delpassand, Ebrahim S.
Weber, Wolfgang A.
Herrmann, Ken
Czernin, Johannes
Eiber, Matthias
Hofman, Michael S.
[J]. EUROPEAN UROLOGY, 2020, 78 (02) : 148 - 154
[6] Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Jang, Albert
Kendi, Ayse T.
Sartor, Oliver
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[7] Soydal C, 2016, Klin Nukleer Tap, V41, P159
[8] Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?
Zhang-Yin, Jules
[J]. BIOMEDICINES, 2024, 12 (07)

← 1 →